Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

医学 叶黄素 吉西他滨 伊立替康 内科学 胰腺癌 佐剂 肿瘤科 辅助治疗 癌症 结直肠癌
作者
Thierry Conroy,Florence Castan,Anthony Lopez,Anthony Turpin,Méher Ben Abdelghani,Alice C. Wei,Emmanuel Mitry,James Biagi,Ludovic Evesque,Pascal Artru,Thierry Lecomte,Éric Assenat,Lucile Bauguion,Marc Ychou,Olivier Bouché,Laure Monard,Aurélien Lambert,Pascal Hammel,Éric François,Jean‐François Ramée
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (11): 1571-1571 被引量:196
标识
DOI:10.1001/jamaoncol.2022.3829
摘要

Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase 3 randomized clinical trial was conducted at 77 hospitals in France and Canada and included patients aged 18 to 79 years with histologically confirmed pancreatic ductal adenocarcinoma who had undergone complete macroscopic (R0/R1) resection within 3 to 12 weeks before randomization. Patients were included from April 16, 2012, through October 3, 2016. The cutoff date for this analysis was June 28, 2021.A total of 493 patients were randomized (1:1) to receive treatment with modified FOLFIRINOX (oxaliplatin, 85 mg/m2 of body surface area; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; and fluorouracil, 2400 mg/m2, every 2 weeks) or gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks) as adjuvant therapy for 24 weeks.Primary end point was disease-free survival. Secondary end points included overall survival, metastasis-free survival, and cancer-specific survival. Prognostic factors for overall survival were determined.Of the 493 patients, 216 (43.8%) were women, and the mean (SD) age was 62.0 (8.9) years. At a median of 69.7 months' follow-up, 367 disease-free survival events were observed. In patients receiving chemotherapy with modified FOLFIRINOX vs gemcitabine, median disease-free survival was 21.4 months (95% CI, 17.5-26.7) vs 12.8 months (95% CI, 11.6-15.2) (hazard ratio [HR], 0.66; 95% CI, 0.54-0.82; P < .001) and 5-year disease-free survival was 26.1% vs 19.0%; median overall survival was 53.5 months (95% CI, 43.5-58.4) vs 35.5 months (95% CI, 30.1-40.3) (HR, 0.68; 95% CI, 0.54-0.85; P = .001), and 5-year overall survival was 43.2% vs 31.4%; median metastasis-free survival was 29.4 months (95% CI, 21.4-40.1) vs 17.7 months (95% CI, 14.0-21.2) (HR, 0.64; 95% CI, 0.52-0.80; P < .001); and median cancer-specific survival was 54.7 months (95% CI, 45.8-68.4) vs 36.3 months (95% CI, 30.5-43.9) (HR, 0.65; 95% CI, 0.51-0.82; P < .001). Multivariable analysis identified modified FOLFIRINOX, age, tumor grade, tumor staging, and larger-volume center as significant favorable prognostic factors for overall survival. Shorter relapse delay was an adverse prognostic factor.The final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.EudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吃饱饱完成签到 ,获得积分10
刚刚
彭于晏应助大力绿柏采纳,获得10
1秒前
1秒前
ri_290完成签到 ,获得积分10
2秒前
贾克斯发布了新的文献求助10
2秒前
何处芳歇发布了新的文献求助10
2秒前
小当家完成签到,获得积分10
2秒前
nightmare发布了新的文献求助10
3秒前
Ava应助独特乘云采纳,获得10
5秒前
义气黄焖排骨完成签到,获得积分10
5秒前
古藤完成签到 ,获得积分10
6秒前
shinian完成签到 ,获得积分10
6秒前
JamesPei应助nightmare采纳,获得10
7秒前
8秒前
9秒前
十年完成签到 ,获得积分10
10秒前
wwl发布了新的文献求助10
12秒前
13秒前
默默千亦完成签到 ,获得积分10
13秒前
贾克斯发布了新的文献求助10
14秒前
撸撸大仙完成签到,获得积分20
15秒前
打我呀发布了新的文献求助10
15秒前
16秒前
Jasper应助体贴的之卉采纳,获得10
17秒前
18秒前
18秒前
19秒前
ScholarZmm完成签到,获得积分10
20秒前
21秒前
22秒前
hzx发布了新的文献求助10
22秒前
22秒前
24秒前
saisyo发布了新的文献求助10
24秒前
24秒前
田様应助不发SCI不改名采纳,获得10
25秒前
幸福大白发布了新的文献求助30
26秒前
GS11发布了新的文献求助10
26秒前
Nitr0ce1L发布了新的文献求助10
27秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174